Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aztreonam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.52 |
| ▸ | PGR | P06401 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aztreonam SCHEMBL10674684 | 1.00 | ESR1 (1.00) | ESR1USP2KDM4ENR1I2PGR | |
| Aztreonam SCHEMBL16863406 | 1.00 | ESR1 (1.00) | ESR1USP2KDM4ENR1I2PGR | |
| Aztreonam SCHEMBL4459605 | 1.00 | ESR1 (1.00) | ESR1USP2KDM4ENR1I2PGR | |
| Aztreonam SCHEMBL4469609 | 1.00 | ESR1 (1.00) | ESR1USP2KDM4ENR1I2PGR | |
| Aztreonam SCHEMBL9424911 | 1.00 | ESR1 (1.00) | ESR1USP2KDM4ENR1I2PGR | |
| Aztreonam SCHEMBL37512 | 1.00 | ESR1 (1.00) | ESR1USP2KDM4ENR1I2PGR | |
| Aztreonam SCHEMBL10464547 | 1.00 | ESR1 (1.00) | ESR1USP2KDM4ENR1I2PGR | |
| Aztreonam SCHEMBL26423 | 1.00 | ESR1 (1.00) | ESR1USP2KDM4ENR1I2PGR | |
| Aztreonam SCHEMBL14209115 | 1.00 | ESR1 (1.00) | ESR1USP2KDM4ENR1I2PGR | |
| Aztreonam SCHEMBL10516547 | 1.00 | ESR1 (1.00) | ESR1USP2KDM4ENR1I2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 38267 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| US-12637481-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2026-05-26 | — | — | US | claimed |
| CN-122071712-A | Beta-lactam antibiotic whole-cell biosensor, construction method and application | 中国科学院天津工业生物技术研究所 | 2026-05-22 | — | — | CN | claimed |
| CN-117305079-B | Method for detecting drug resistance heterogeneity of bacteria based on single-cell microfluidic system and application thereof | 天津现代创新中药科技有限公司 | 2026-05-22 | — | — | CN | claimed |
| WO-2026107208-A1 | COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026104587-A1 | CYCLIC BORONIC ACID ESTERS USEFUL AS ADJUVANTS IN THE TREATMENT OF BACTERIAL INFECTIONS | ADJUTEC PHARMA AS (NO) | 2026-05-21 | — | — | WO | claimed |
| WO-2026099472-A1 | LIPOSOMAL COMPOSITIONS FOR TREATMENT OF INFLAMMATION | Universität Bern (CH) | 2026-05-15 | — | — | WO | claimed |
| CN-121622671-B | Application of meropenem or aztreonam combined with nalidixic acid in preparation of antibacterial drugs | 山东省妇幼保健院 | 2026-05-15 | — | — | CN | claimed |
| EP-4739326-A2 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR Biome ApS (DK) | 2026-05-13 | — | — | EP | claimed |
| CN-116178363-B | Method for preparing beta-crystal form aztreonam | 广安凯特制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-4775670-A | BACTERICIDES, ANTIBIOTICS | E. R. SQUIBB & SONS, INC. (US) | 1988-10-04 | — | — | US | claimed |
| CN-87106855-A | The manufacture method of composition for oral liquid | — | 1988-04-20 | — | — | CN | claimed |
| EP-0263493-A2 | Pharmaceutic preparation to improve the gastro-intestinal resorption | F. HOFFMANN-LA ROCHE AG (CH) | 1988-04-13 | — | — | EP | claimed |
| EP-0048953-B1 | BETA-LACTAM ANTIBIOTICS | E.R. Squibb & Sons, Inc. (US) | 1988-03-09 | — | — | EP | claimed |
| EP-0088847-B1 | THIAZOLE DERIVATIVES AND THEIR USE IN THE MANUFACTURE OF BETA-LACTAM ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 1986-02-26 | — | — | EP | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
| US-4503040-A | 6-(Aminoacyloxymethyl)penicillanic acid 1,1-dioxides as beta-lactamase inhibitors | PFIZER INC. (US) | 1985-03-05 | — | — | US | claimed |
| EP-0108295-A1 | Oral dosage form | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-05-16 | — | — | EP | claimed |
| EP-0088847-A1 | Thiazole derivatives and their use in the manufacture of beta-lactam antibiotics | GLAXO GROUP LIMITED (GB) | 1983-09-21 | — | — | EP | claimed |
| EP-0048953-A2 | Beta-lactam antibiotics | E.R. Squibb & Sons, Inc. (US) | 1982-04-07 | — | — | EP | claimed |